Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Unusually-High Trading Volume - Here's What Happened

Key Points

• Chugai experienced an unusually large intraday volume spike of about 874,583 shares, a 351% increase from the prior session, with the stock trading near $26.98 (up from $26.52).
• Analyst sentiment is bullish after recent upgrades by UBS and SMBC Nikko to Strong Buy, and the consensus rating on the stock is currently Strong Buy.
• Fundamentals show a market cap of $89.22 billion and a P/E of 31.16; the company reported last-quarter EPS of $0.25 on $2.25 billion revenue, with a 22% ROE and 34.47% net margin, and analysts forecast about 0.74 EPS for the year.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) saw unusually-strong trading volume on Tuesday . Approximately 874,583 shares traded hands during mid-day trading, an increase of 351% from the previous session's volume of 193,766 shares.The stock last traded at $26.98 and had previously closed at $26.52.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on CHGCY shares. UBS Group raised shares of Chugai Pharmaceutical to a "strong-buy" rating in a research report on Tuesday, January 27th. Smbc Nikko Sec. raised shares of Chugai Pharmaceutical to a "strong-buy" rating in a research note on Wednesday, February 25th. Two investment analysts have rated the stock with a Strong Buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Strong Buy".

Chugai Pharmaceutical Trading Up 2.2%

The firm's 50-day moving average price is $29.13 and its two-hundred day moving average price is $26.43. The stock has a market cap of $89.22 billion, a PE ratio of 31.16 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last announced its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $2.25 billion for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%. On average, analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai's activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.